New App Helps Predict Pediatric Transplant Need Celebrating the repurposed use of Livmarli for pediatric rare liver disease patients Global Liver Institute (GLI) celebrates a major...
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S. This breakthrough follows years of NASH patient-led multi-stakeholder...
White House declares April 2024 as Cancer Prevention and Early Detection Month This landmark announcement from the White House follows ongoing advocacy efforts, including a letter to President Joe...
Healthy Eating, Healthy Liver: The Links Between Nutrition and Liver Wellness Maintaining optimal liver health is crucial, given the liver's pivotal role as a major detoxifying organ. The...
GLI Commends Repurposed Livmarli’s FDA Approval for Patients over 5 with PFIC(Washington, D.C. March 14, 2024) –Global Liver Institute (GLI) celebrates a win for rare disease patients with the...
7th Annual Global Fatty Liver Day, formerly known as International NASH Day, is less than 3 months away! Fatty liver disease is a widespread issue that often goes undetected until it’s too late. It...
GLI Commends Repurposed Livmarli’s FDA Approval for Patients over 5 with PFIC(Washington, D.C. March 14, 2024) –Global Liver Institute (GLI) celebrates a win for rare disease patients with the...
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient PopulationGLI Celebrates Approval of Madrigal Pharmaceutical’s Rezdiffra™ (resmetirom) as Milestone for Liver...
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis Madrigal Pharmaceuticals...
Congress continues to narrowly avert a government shutdown, most recently with yet another Continuing Resolution to extend government funding through later in March. Join Global Liver Institute to...
Recent News
Global Liver Institute Statement on the Passing of Dr. Stephen HarrisonThe entire field of liver health has experienced an incredible loss. It is with great sadness that Global Liver Institute, our Liver Action Network members and the patient community express our...
Addressing Disparities in Organ Transplantation: A Call for Equitable Healthcare Introduction Organ transplantation has revolutionized modern medicine, offering a beacon of hope for individuals battling end-stage organ failure. At the same time, it is intricately...
Congress begins Fiscal Year 2025 appropriations process and the Administration approves new treatments improving the lives of liver disease patients. Join Global Liver Institute to Push Congress to Advance Priority Bills and Support Agency Efforts.Congress finalizes...
New App Helps Predict Pediatric Transplant Need Celebrating the repurposed use of Livmarli for pediatric rare liver disease patients Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s...
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S. This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development. The hope...
